Background & Aims: The use of non-selective beta-blockers has been associated
| INTRODUC TI ON
Patients with cirrhosis and portal hypertension develop a hyperdynamic circulatory state characterized by splanchnic and peripheral vasodilation and increased plasma volume as a result of the excessive production of vasodilators. 1 The progression of the disease is followed by an increased activity of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system that act as counterregulatory mechanisms 2 that fail to reverse the vasodilation due to the important and sustained increase of vasodilator agents such as nitric oxide (NO) 1 and a loss of alpha and beta adrenergic response. 3, 4 Spontaneous bacterial peritonitis (SBP) is a bacterial infection frequently observed in patients with cirrhosis. 5 This infection is due to bacterial translocation (BT), defined as the passage of gram-negative bacteria or their products, which act as pathogenassociated molecular patterns (PAMPs), from the intestinal lumen through the intestinal wall to the mesenteric lymph nodes. 6 Our group has shown that the existence of bacterial DNA (bactDNA) in the blood and ascitic fluid (AF) of hospital patients with cirrhosis and noninfected ascites 7, 8 constitutes a marker of BT. 9 The presence of bactDNA is associated with a higher peritoneal nitric oxide (NO) production, 10 an activation of the complement system 11 and, in general, a higher soluble immune response not related to endotoxin 12 similar to that observed in patients with SBP. 13 Patients who present with bactDNA in blood during an episode of ascites have reduced survival in the next year.
14 Non-selective beta-blockers (NSBBs) remain the main treatment of portal hypertension because of their efficacy at preventing variceal bleeding. 15 The treatment with NSBB of patients with cirrhosis has been associated with lower rates of infections, 16 decreased abnormal intestinal permeability and serum levels of LBP and IL-6, 17 reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. 18 It is unknown if treatment with these drugs also modifies the inflammatory response to the presence of PAMPs without an overt clinical infection. Conversely, it has been shown that NSBB treatment increased the risks for hepatorenal syndrome and acute kidney injury in severely infected patients with cirrhosis. 19 In these patients, a high production of proinflammatory cytokines seems to play a role in the worsening of liver function. 20 Experimental models of bacterial peritonitis or splanchnic sympathectomy have shown that SNS activation is followed by lower levels of peritoneal secretion of TNF-alpha and limited phagocytic activity of peritoneal macrophages, 21 while SNS suppression is associated with a reduced rate of Escherichia coli bacterial translocation. 22 The SNS is known to produce most of these effects through beta-adrenergic receptors. 23 Then, the SNS blockade could explain part of the reduction in mortality of patients with cirrhosis treated with NSBB due to the down-regulation of bacterial translocation rates, 22, 24 in addition to the haemodynamic effects or the ability of the SNS to modulate other systems.
The present study was designed to investigate the effects of beta-blockers on the systemic immune response to the presence of bactDNA in patients with cirrhosis and ascites.
| PATIENTS AND ME THODS
We conducted a prospective trial in patients with cirrhosis and ascites. Cirrhosis was diagnosed by histology or by clinical, laboratory, and/or ultrasonographic findings. Patients were included during an episode of ascites decompensation. Exclusion criteria were the IFN-gamma and IL10 in response to the presence of bacterial DNA. Patients treated with non-selective beta-blockers showed higher basal inflammatory activity that did not change with the presence of bacterial DNA. Monocytes and granulocytes from patients treated with non-selective beta-blockers showed a significantly increased phagocytic capacity in the presence of bacterial DNA.
Conclusions:
In patients with cirrhosis, chronic treatment with beta-blockers is associated with a higher unstimulated production of serum cytokines and an increased phagocytic activity in the presence of bacterial DNA.
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• The detection rate of bacterial DNA in the blood was the same (33%) for patients not treated and treated with non-selective beta-blockers.
• Patients with cirrhosis chronically treated with non-selective beta-blockers show an increased systemic inflammatory response during an ascites episode.
• Chronic treatment with beta-blockers increases the Universitario de Alicante approved the study protocol, and all patients provided informed consent for inclusion in the study.
Patients were studied in the course of their admission to the hospital for an episode of ascitic decompensation. After signing the informed consent, blood samples were obtained after the patient had been in the supine position for at least 30 minutes in a quiet at-
mosphere. An automated measurement of blood pressure and heart rate was taken, and heart rate variability was recorded for 30 minutes (S810i Polar heart rate monitor; software RHRV version 4.0).
Blood samples were inoculated under aseptic conditions in rubber-sealed sterile Vacutainer SST II tubes (BD Diagnostics, Belgium) that were never exposed to free air. Serum and plasma samples were stored at −80°C until the analyses.
To detect and identify the presence of bactDNA fragments in the blood, a broad-range polymerase chain reaction (PCR) and partial nucleotide sequencing analysis was performed according to the methodology described previously. NO levels in serum samples were calculated by measuring the conversion of nitrate to nitrite by the enzyme nitrate reductase using an ELISA (KGE001, R&D Systems) based on the Griess reaction. 25 The phagocytic activity was evaluated using a Phagotest kit 
| Statistical analysis

| RE SULTS
Sixty-three consecutively admitted patients with cirrhosis were included in the study during episodes of decompensation by ascites. Table 1 . Patients treated with NSBBs were younger, more frequently had gastroesophageal varices, and had lower counts of platelets in the blood and leukocytes in the ascitic fluid than patients not treated with these drugs.
As expected, patients treated with NSBBs showed a significantly lower heart rate (73 ± 9 vs 84 ± 18; P value = .01) and longer mean normal to normal intervals (627 ± 170 vs 764 ± 170 ms; P value = .04). No other significant differences in heart rate variability Table 2 .
Specifically, it was this group of patients who had significantly higher serum concentrations of the proinflammatory cytokines IL6
and IFN-gamma and the anti-inflammatory cytokine IL10 (Table 2) .
On the other hand, patients treated with NSBB showed a different activation profile characterized by higher basal levels of inflammatory activity expressed by increased levels of serum IL6 that did not change in response to the presence of bactDNA (Table 2 ).
In multiple linear regression analyses, serum IL6 levels were only significantly related with NSBB. On the other hand, IL10 levels were significantly associated with LPS concentrations, while IFN-gamma concentrations were related with the Child-Pugh score ( Table 3 ).
The in vitro percentage of granulocytes and monocytes that can 
| D ISCUSS I ON
In this investigation, we provide evidence that patients with cirrhosis chronically treated with NSBBs respond differently during an episode of decompensation by ascites than non-treated patients to the presence of PAMPs. The chronic use of NSBBs in patients without bactDNA is associated with higher basal levels of cytokines IL6, IFN-gamma and IL10, similar to those observed in patients not treated with NSBBs but exposed to bactDNA. These results are in agreement with the proposed immune inhibitory effect of SNS through beta-adrenoceptors that would be reversed by treatment with NSBB. 23, 26 In our study, multivariate analysis showed that NSBB treatment is significantly associated with higher concentrations of serum IL6
independent of the presence of PAMPs. Cirrhotic patients with
bacterial infections display marked and sustained increases in TNFalpha and IL-6 blood levels that have been related to the development of cirrhotic decompensation and poor survival independent of liver dysfunction. 27 NSBB treatment increases the risks for hepatorenal syndrome and acute kidney injury in severely infected patients with cirrhosis 19 and high production levels of proinflammatory cytokines. 20 These data suggest that the increase in IL-6 associated with treatment with NSBB could be implicated in the worst prognosis of these patients after developing an infection, even though the NSBBs reduce the risk of infection. This effect would be independent of the mechanism by which the NSBBs reduce the risk of infection in patients with cirrhosis. The significance of these findings AF, ascitic fluid; ALT, alanine aminotransferase; bactDNA, bacterial DNA; NSBB, non-selective beta-blockers; PMN, polymorphonuclears; PPI, proton pump inhibitor; SID, selective intestinal decontamination. Data are mean ± standard deviation or frequencies.
in patients with the presence of PAMPs is unknown and should be evaluated in future studies.
Potentially beneficial new therapeutic uses of NSBB have been proposed, such as the prevention of hepatocarcinoma or the reduction of bacterial infection episodes. 16, 28 Merli et al 16 found that the use of NSBBs was a protective factor against overt clinical infections.
Reiberger et al 17 showed that in cirrhotic patients, NSBB treatment decreased abnormal intestinal permeability and serum levels of LBP and IL-6. Our data support the existence of different immune activation in cirrhotic patients treated with NSBB who showed higher serum levels of IL6, IFN-gamma and IL10 in the absence of infection or circulating PAMPs, which could favour the existence of an unfavourable environment for the development of an infectious process.
However, in our study, the bacterial DNA detection rate was similar in patients treated and not treated with NSBB, suggesting a null effect of NSBB treatment on bacterial translocation rates. We do not know if differences in the BT rate according to NSBB treatment would have be found if we had included patients with cirrhosis without ascitic decompensation, a situation that favours BT, or if we had used a surrogate marker of BT other than bactDNA.
This study had limitations related to our study population. Elevated ascites PMN counts of more than 100 cells/μL has been associated with a significant risk for SBP development. 30 In our study, patients treated with NSBBs showed a significantly lower count of leukocytes in ascitic fluid despite a lack of reduction in blood leukocytes. Total PMN counts in AF were similar in patients treated and not treated with NSBB and were clearly below the cut-point of 100 cells/ μL previously associated with the risk of developing SBP. Whether differences in AF leukocyte levels could be explained by a leukocyte redistribution influenced by NSBB treatment, as has been described in heart failure, has yet to be confirmed in specific studies. 31 Beta-adrenoceptor activation of human monocytes has been associated with a reduction of C. albicans phagocytosis. 32 In our study, the phagocytic ability of the monocytes and granulocytes in 
CO N FLI C T O F I NTE R E S T
The authors do not have any disclosures to report.
O RCI D
Pedro Zapater
http://orcid.org/0000-0001-7927-858X
